OnabotulinumtoxinA for Systemic Sclerosis-associated Raynaud’s Phenomenon: A Multi-Institutional Study on Accessibility and Effectiveness

November 2021 | Volume 20 | Issue 11 | Editorials | 1257 | Copyright © November 2021

Published online October 27, 2021

Bina Kassamali BA,^a,b,* Sheena Desai BS,^a,c,* Michelle S. Min MD MS,^a,b Daniel R. Mazori MD,^a,b Camila Villa-Ruiz MPH,^a,d Kylee JB Kus,^a,e BS Gabriela A. Cobos MD,^a,b Joseph Merola MD MMSc^a,b,f Avery LaChance MD MPH,^a,b,# Ruth Ann Vleugels MD MPH MBA^a,b,#

^aDepartment of Dermatology, Brigham and Women's Hospital, Boston, MA
^bHarvard Medical School, Boston, MA
^cTufts University School of Medicine, Boston, MA
^dPonce Health Sciences University, School of Medicine, Ponce, PR
^eOakland University William Beaumont School of Medicine, Rochester, MI
^fDepartment of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA

*Denotes co-first authors
#Denotes co-senior authors